08/11/2018

INPhINIT Doctoral Fellowship Programme hosting offer: MOLECULAR BASIS FOR HETERORRESISTANCE TO ANTIBIOTICS IN BACTERIA CAUSING NOSOCOMIAL INFECTIONS


  • OFFER DEADLINE
    06/02/2019 00:00 - Europe/Brussels
  • EU RESEARCH FRAMEWORK PROGRAMME
    Not funded by an EU programme
  • LOCATION
    Spain, Córdoba
  • ORGANISATION/COMPANY
    IMIBIC (Maimonides Biomedical Research Institute)
  • LABORATORY
    https://www.imibic.org/grupo/44

IMIBIC HOSTING OFFER:

La Caixa INPhINIT INCOMING Doctoral Fellowship Programme

CENTRE DESCRIPTION

IMIBIC, located in Cordoba, southern Spain, is a partnership between the University of Cordoba (UCO) and the Reina Sofia University Hospital. IMIBIC offers a multidisciplinary environment focused on results-oriented research and based on precision medicine and excellence in science. IMIBIC is accredited with the Excellence distinction from the National Institute of Health Carlos III and the “HR Excellence in Research” by the EC.

The Institute is structured in 44 research groups that cooperate in the implementation of five scientific programmes. IMIBIC offers an active environment in which to conduct high-level scientific research. Regular seminars and research events offer the opportunity to meet with national and international experts covering a diverse range of topics in biomedicine. Advanced training of our PhD students is provided primarily through the Doctoral Program in Biomedicine (UCO), hosted at the IMIBIC and integrated by leading scientists from the University and the Hospital. Results from research activities are exposed yearly in the IMIBIC Young Investigator Meetings, providing an ideal environment to strengthen the skills and knowledge of young scientists and to foster translational research by bringing together experimental basic and medical sciences.

IMIBIC is young and fast growing research center. It operates in a brand new building located within the UCO Health Sciences Campus and next to the University Hospital. It hosts over 600 researchers, and offers the latest technology, equipment and laboratories to support the technical needs of the research community.

Cordoba is a medium sized city located in the hearth of Andalusia, with excellent transport connections to the main cities of Spain and both to the Mediterranean and Atlantic coasts. Rich in history and culture, Cordoba is a friendly and welcoming city, with high standard of living, making it an ideal location for international students wishing to carry out their doctoral studies in Spain.

GROUP LEADER

Dr.Luis Martínez-Martínez (luis.martinez.martinez.sspa@juntadeandalucia.es)

RESEARCH PROJECT/RESEARCH GROUP

IMIBIC group GC24: https://www.imibic.org/grupo/44

POSITION DESCRIPTION

Antimicrobial resistance is a major health problem worldwide. This is a scientific area of increasing relevance, with multiple efforts aimed to a better understanding of the involved biological mechanisms.

It is well known that antimicrobial agents select for resistant mutants presenting heritable genetic alterations. The minimal inhibitory concentration (MIC) of antibiotics for those mutants is higher than that for the original population. On the other hand, some bacteria in a population can survive the lethal action of a bactericidal agent and can generate a new population for which the MIC is the same than for the original population. The later phenomenon is known as [bacterial] persistence, and the corresponding surviving bacteria are named persisters.

When heteroresistance is observed in bacterial populations, it is usually assumed that this is due to the selection of mutants and, very rarely, detailed studies have been performed to evaluate the contribution of persisters in the observed heteroresistance. There is not much information about the clinical importance of persistance. The actual mechanisms responsible for bacterial persistance and if they are the same for different antimicrobial families are not currently known.

This is an in vitro study in which clinical isolates and laboratory mutants of Klebsiella pneumoniaeAcinetobacter baumannii and P. aeruginosa will be evaluated. MICs will be determined following CLSI guidelines. The population analysis profile (PAP) method will be used for evaluating heteroresistance to carbapenems and polymyxins, using conventional culture media and minimal medium. For a selected group of isolates (in which heteroresistance has been observed), the growing colonies will be defined as either mutants or persisters. Whole genome sequencing will be used to evaluate (mutated) genes involved in heteroresistance.

-Job position description:

Predoctoral position in a consolidated research group (GC024); IMIBIC, Córdoba, Spain. The group is integrated into the Spanish Network for Research in Infectious Diseases (REIPI, http://reipi.org/).

The candidate should have graduated in Medicine, Pharmacy, Biology or related biomedical areas. He/She will apply and develop phenotypic and molecular tools to the study of multidrug-resistant bacteria, including reference methods for antibiogram, proteomic and molecular identification at species level, molecular typing, detection of resistance genes using PCR and related techniques and next-generation sequencing (NGS), and bioinformatic analysis of NGS data. The candidate will integrate into a group with large experience in the study of microbiological aspects and clinical relevance of antimicrobial resistance, maintaining a close relationship with infectologists and other clinicians interested in infections.

Eligibility Criteria

1) At the call deadline (6th Feb 2019), applicants must be in the first four years (full-time equivalent research experience) of their research careers and not yet have been awarded a doctoral degree.

2) At the time of recruitment, candidates must comply with one of the following options:

  • To have completed the studies that lead to an official university degree adapted to the European Higher Education Area awarding 300 ECTS credits, of which at least 60 ECTS credits must correspond to master level.
  • To have completed a degree in university not adapted to the European Higher Education Area that gives access to doctoral studies. The verification of an equivalent level of studies to the ones mentioned above will be made by the university when the admission procedure starts.

3) Candidates must not have resided or have carried out their main activity (work, studies, etc.) in Spain for more than 12 months in the 3 years immediately prior to the call deadline (6th Feb 2019). Short stays, such as holidays, done in a country other than their country of usual residence (where they carried out their main activity), will be considered as time spent in their country of usual residence.

4) Candidates must have a demonstrable level of English (B2 or higher).

5) Only candidates whose applications meet all the requirements of the call may be accepted.

 

You can find this offer via the Offer Finder, available at: https://hosts.lacaixafellowships.org/finder

Select “IMIBIC – Maimonides Biomedical Research Institute to Cordoba” from the dropdown list under “RESEARCH CENTER”

You can also search the position by its title "MOLECULAR BASIS FOR HETERORRESISTANCE TO ANTIBIOTICS IN BACTERIA CAUSING NOSOCOMIAL INFECTIONS" under "SEARCH BY PROJECT TITLE / JOB POSITION TITLE".

 

How to Apply:

If you want to apply for an INPhINIT fellowship, click on the link below to create your personal account and fill in the on-line application form: https://www.lacaixafellowships.org/index.aspx

 

Schedule:

6 February 2019: Application deadline.

20 February 2019: Deadline for submitting the language certificate.

23 April 2019: Notification of the shortlist results.

28 and 29 May 2019: Face-to-face interviews in Barcelona.

4 June 2019: Publication of the final list of selected candidates.

4 June 2019 to 5 July 2019: Matching between the research centres – fellows.

 

More Information:

Call for applications:

https://obrasociallacaixa.org/en/investigacion-y-becas/programa-de-becas-de-posgrado/inphinit/incoming

Programme Rules: https://obrasociallacaixa.org/documents/10280/590054/inphinit_incoming_2019_en.pdf/2fa7e823-a7c7-22d8-98a7-dd14a0d0171f

Email:

international@imibic.org